学部概况
教师队伍
人才培养
学院、部
临床医院
科学研究
管理服务
交流合作
北医产业
ENGLISH
 
 
 
 招生就业
 招聘信息
 校园文化
 服务平台
 校内信息
 信息周刊
首页 >> 学术讲座 >>

(3月14日)北京大学基础医学院院长论坛
发布日期:2019-03-12 浏览次数: 字号:[ ]

  报告题目:“Investigational therapies for hepatitis B and liver cancer: will anything really work?”

  报告人:Timothy M. Block

  时间: 2019年3月14日(周四)下午15:00-17:00

  地点:北京大学医学部逸夫楼一层114会议室

  主持人:鲁凤民 教授

  报告人简介:

  

  

  Timothy M. Block, Ph.D., M.B. is President and Co-founder of the Hepatitis B Foundation; the Baruch S. Blumberg Institute; and the Pennsylvania Biotechnology Center. The Baruch S. Blumberg Institute is a nonprofit translational research organization, where Nobel Prize winning scientist Baruch S. Blumberg, worked part time, until his passing, in 2011. Dr. Block’s work with Baruch S Blumberg, Anand Mehta and Raymond Dwek, pioneered the use of glycoproteomics for detection of biomarkers of liver cancer, leading to the use of GP73 and core fucosylated serum proteins as risk stratifiers for liver cirrhosis and hepatocellular carcinoma. His work with Ying Su led to use of “microDNA” detected in the urine as a cancer marker. More recently, he and his colleagues have identified small molecule inhibitors of hepatitis B virus, which are in clinical phase human testing, today.

  

  He is scientific co-founder of several life sciences companies, co-inventor on 20 issued patents and 23 applications, has co-authored more than 240 scholarly papers, and was named a “Visionary in Hepatitis” by the World Hepatitis Alliance in 2017. He was elected (2017) US National Academy of Inventors, awarded an honorary Doctor (1999), and is Adjunct Professor at Geisinger Commonwealth School of Medicine and the University of Pennsylvania School of Medicine.              

  欢迎广大师生参加!

  




pc蛋蛋大小玩法 关闭窗口

版权所有:北京大学医学部 北京市海淀区学院路38号  邮编:100191  京ICP备05065075号-19